English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Transcriptional reprogramming by mutated IRF4 in lymphoma

MPS-Authors
/persons/resource/persons204283

Cauchy,  Pierre
Max Planck Institute of Immunobiology and Epigenetics, Max Planck Society;

Huber,  Lionel
Max Planck Institute of Immunobiology and Epigenetics, Max Planck Society;

Obier,  Nadine
Max Planck Institute of Immunobiology and Epigenetics, Max Planck Society;

/persons/resource/persons191076

Grosschedl,  Rudolf
Department of Cellular and Molecular Immunology, Max Planck Institute of Immunobiology and Epigenetics, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

10.1038_s41467-023-41954-8.pdf
(Publisher version), 5MB

Supplementary Material (public)
There is no public supplementary material available
Citation

Schleussner, N., Cauchy, P., Franke, V., Giefing, M., Fornes, O., Vankadari, N., et al. (2023). Transcriptional reprogramming by mutated IRF4 in lymphoma. Nature Communications, 14: 6947. doi:10.1038/s41467-023-41954-8.


Cite as: https://hdl.handle.net/21.11116/0000-000F-3D38-F
Abstract
Disease-causing mutations in genes encoding transcription factors (TFs) can affect TF interactions with their cognate DNA-binding motifs. Whether and how TF mutations impact upon the binding to TF composite elements (CE) and the interaction with other TFs is unclear. Here, we report a distinct mechanism of TF alteration in human lymphomas with perturbed B cell identity, in particular classic Hodgkin lymphoma. It is caused by a recurrent somatic missense mutation c.295 T > C (p.Cys99Arg; p.C99R) targeting the center of the DNA-binding domain of Interferon Regulatory Factor 4 (IRF4), a key TF in immune cells. IRF4-C99R fundamentally alters IRF4 DNA-binding, with loss-of-binding to canonical IRF motifs and neomorphic gain-of-binding to canonical and non-canonical IRF CEs. IRF4-C99R thoroughly modifies IRF4 function by blocking IRF4-dependent plasma cell induction, and up-regulates disease-specific genes in a non-canonical Activator Protein-1 (AP-1)-IRF-CE (AICE)-dependent manner. Our data explain how a single mutation causes a complex switch of TF specificity and gene regulation and open the perspective to specifically block the neomorphic DNA-binding activities of a mutant TF.